ACADIA PHARMACEUTICALS INC. (ACAD) /
The cash flow of ACADIA PHARMACEUTICALS INC. over the past 10 years
Chart ACADIA PHARMACEUTICALS INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, ACADIA PHARMACEUTICALS INC.'s operating cash flow was $109.84M and its capital expenditures $4.69M, leaving free cash flow of $105.15M. Free cash flow was above zero in 3 of the 10 years shown. It ranged from -$218.57M in fiscal 2017 to $157.2M in fiscal 2024. Capital expenditures were highest in fiscal 2020, at $7.59M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $109.84M | $4.69M | $105.15M |
| 2024ended Dec 31, 2024 | $157.72M | $523K | $157.2M |
| 2023ended Dec 31, 2023 | $16.7M | $50K | $16.65M |
| 2022ended Dec 31, 2022 | -$114.03M | $0 | -$114.03M |
| 2021ended Dec 31, 2021 | -$125.66M | $1.12M | -$126.78M |
| 2020ended Dec 31, 2020 | -$136.17M | $7.59M | -$143.75M |
| 2019ended Dec 31, 2019 | -$151.13M | $1.13M | -$152.26M |
| 2018ended Dec 31, 2018 | -$167.47M | $2.1M | -$169.57M |
| 2017ended Dec 31, 2017 | -$217.76M | $812K | -$218.57M |
| 2016ended Dec 31, 2016 | -$208.41M | $1.51M | -$209.91M |
Fiscal years as ACADIA PHARMACEUTICALS INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on ACADIA PHARMACEUTICALS INC.
- The revenue of ACADIA PHARMACEUTICALS INC.
- The profitability of ACADIA PHARMACEUTICALS INC.
- The debt of ACADIA PHARMACEUTICALS INC.
- All of ACADIA PHARMACEUTICALS INC.'s financials, charted
Companies of a similar size
- HURNHURON CONSULTING GROUP INC.
- SDRLSEADRILL LIMITED
- OSISOSI SYSTEMS, INC.
- PFSIPennyMac Financial Services, Inc.
- HIWHIGHWOODS PROPERTIES, INC.
Not investment advice. This page shows what ACADIA PHARMACEUTICALS INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.